Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRAL vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tralokinumab is a human monoclonal antibody that specifically binds to interleukin-13 (IL-13) and inhibits its interaction with the IL-13 receptor α1 and α2 subunits. This blockade reduces IL-13-mediated signaling, which is implicated in the pathophysiology of atopic dermatitis, including inflammation, pruritus, and skin barrier dysfunction.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Treatment of moderate-to-severe atopic dermatitis in adults whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
10 mg intravenously once daily
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal elimination half-life is 12–18 hours in patients with normal renal function (Cr Cl >90 m L/min). In moderate renal impairment (Cr Cl 30–59 m L/min), half-life extends to 24–36 hours. Clinical context: Dosing interval adjustment required for Cr Cl <60 m L/min.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Tralokinumab is a monoclonal antibody, expected to be degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or enzymes are involved.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Approximately 70% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion; 30% is eliminated in feces via biliary secretion. Total renal clearance accounts for 85% of systemic clearance.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
92% bound primarily to human serum albumin; minor binding to alpha-1-acid glycoprotein (3%). Binding is concentration-independent over therapeutic range.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Vd is 0.25 L/kg (range 0.2–0.3 L/kg), indicating distribution primarily into extracellular fluid. Vd increases to 0.4 L/kg in patients with edema or ascites.
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral bioavailability is 60–75% due to first-pass hepatic metabolism; 90–100% for intramuscular and subcutaneous routes.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
No dose adjustment required for GFR ≥30 m L/min; not recommended for GFR <30 m L/min
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
No dose adjustment for Child-Pugh A; use with caution for Child-Pugh B and C, no specific dose recommendation
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Not approved for pediatric use; safety and efficacy not established
Not approved for pediatric patients <18 years; safety and efficacy not established.
No specific dose adjustment; monitor renal function closely in elderly patients
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
None.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Hypersensitivity reactions (including anaphylaxis) have been reported; discontinue if serious reaction occurs.,Patients with parasitic (helminth) infections should be treated before initiating therapy; monitor during treatment.,Potential for increased risk of infections; consider risks in patients with chronic infections or history of recurrent infections.,Consider vaccination status prior to initiation; avoid live vaccines during treatment.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Known hypersensitivity to tralokinumab or any excipients in the formulation.
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
No specific food interactions known; take with or without food. Grapefruit may alter metabolism; advise limiting grapefruit juice intake.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
TRAL is a monoclonal antibody. No human data available; animal studies did not show teratogenicity at clinically relevant doses. Due to Ig G1 transport across placenta, potential exposure in second and third trimesters. Theoretical risk of immunosuppression in the fetus.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
TRAL is a large monoclonal antibody likely excreted in breast milk in small amounts. M/P ratio not established. Limited data; consider risk-benefit; use caution.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No pharmacokinetic studies in pregnancy. No dose adjustment recommended; weight-based dosing may need adjustment for maternal weight gain, but specific data lacking.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
TRAL is a novel anti-epileptic drug with linear pharmacokinetics; monitor for somnolence, dizziness, and weight gain; adjust dose in renal impairment (Cr Cl < 30 m L/min). Avoid abrupt discontinuation; taper over 2-4 weeks. Drug interactions: induces CYP3A4 and may reduce efficacy of oral contraceptives; valproate increases TRAL levels by 40%.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Take exactly as prescribed; do not stop suddenly without medical advice.,Avoid driving or operating heavy machinery until you know how this medicine affects you.,Report any rashes, swelling, or mood changes immediately.,Use effective contraception; this drug may reduce birth control effectiveness.,Avoid alcohol while taking this medication.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
"Concurrent use of lorazepam, a benzodiazepine, and sertraline, a selective serotonin reuptake inhibitor (SSRI), may result in additive central nervous system (CNS) depression, leading to enhanced sedation, dizziness, and psychomotor impairment. This interaction is primarily pharmacodynamic, involving potentiation of GABAergic effects by lorazepam and sertraline's modulation of serotonergic pathways, which can augment sedative effects. Clinically, patients may experience excessive drowsiness, reduced cognitive function, and increased risk of falls or accidents, particularly during treatment initiation or dose adjustments."
"Axitinib, a tyrosine kinase inhibitor used in renal cell carcinoma, is primarily metabolized by CYP3A4 and also inhibits CYP3A4 and CYP2D6. Sertraline, an SSRI antidepressant, is a substrate of CYP2D6 and to a lesser extent CYP3A4. Coadministration may lead to decreased clearance of sertraline, resulting in elevated sertraline plasma concentrations and increased risk of serotonin-related adverse effects such as serotonin syndrome, QT prolongation, or gastrointestinal disturbances."
"Mequitazine, a first-generation H1-antihistamine, inhibits CYP2D6 and CYP3A4, the primary enzymes responsible for the metabolism of sertraline, a selective serotonin reuptake inhibitor (SSRI). This inhibition can significantly reduce sertraline clearance, leading to increased plasma concentrations, which may elevate the risk of dose-dependent adverse effects such as serotonin syndrome, QT prolongation, and central nervous system depression. Patients may present with symptoms including confusion, tachycardia, hyperthermia, or arrhythmias, particularly at higher doses or in those with underlying risk factors."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRAL vs ABSTRAL, answered by our medical review team.
TRAL is a Opioid Analgesic that works by Tralokinumab is a human monoclonal antibody that specifically binds to interleukin-13 (IL-13) and inhibits its interaction with the IL-13 receptor α1 and α2 subunits. This blockade reduces IL-13-mediated signaling, which is implicated in the pathophysiology of atopic dermatitis, including inflammation, pruritus, and skin barrier dysfunction.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRAL and ABSTRAL depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRAL is: 10 mg intravenously once daily. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRAL and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRAL is classified as Category C. TRAL is a monoclonal antibody. No human data available; animal studies did not show teratogenicity at clinically relevant doses. Due to IgG1 transport across placenta, potential ex. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.